2018
DOI: 10.5606/archrheumatol.2018.6695
|View full text |Cite
|
Sign up to set email alerts
|

Aggressive Kaposi’s Sarcoma Associated With Golimumab Therapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
5
0

Year Published

2018
2018
2022
2022

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 7 publications
0
5
0
Order By: Relevance
“…[ 1 ] Similar to our patient, there have been reported cases of cutaneous KS in patients receiving golimumab, infliximab, and adalimumab therapy. [ 13 14 15 16 17 18 19 ] Gastrointestinal involvement of KS has also been reported in a patient with UC exposed to Infliximab. [ 20 ]…”
Section: Discussionmentioning
confidence: 97%
“…[ 1 ] Similar to our patient, there have been reported cases of cutaneous KS in patients receiving golimumab, infliximab, and adalimumab therapy. [ 13 14 15 16 17 18 19 ] Gastrointestinal involvement of KS has also been reported in a patient with UC exposed to Infliximab. [ 20 ]…”
Section: Discussionmentioning
confidence: 97%
“…To our knowledge, five cases of KS were identified with the use of infliximab, two cases with adalimumab, one with golimumab, and one with certolizumab pegol [7][8][9][10][11][12][13][14][15]. In most of the cases, KS was notably localized to the skin.…”
Section: Discussionmentioning
confidence: 99%
“…16 To our knowledge, five KS cases were identified with the use of infliximab, three cases with adalimumab, one with golimumab, and one with certolizumab pegol. 9,[17][18][19][20][21][22][23][24][25][26] unclear and should be addressed by appropriate studies. In most of the cases, KS was notably localized to the skin.…”
Section: Discussionmentioning
confidence: 99%